Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $136.88

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned a consensus rating of “Buy” from the twelve research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $136.88.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. BidaskClub downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Monday, June 24th. Canaccord Genuity lifted their target price on Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a report on Friday, May 31st. Finally, Wedbush reiterated a “buy” rating and issued a $223.00 target price on shares of Ascendis Pharma A/S in a report on Friday, June 28th.

Shares of Ascendis Pharma A/S stock traded up $1.39 on Wednesday, reaching $115.84. 146,999 shares of the company were exchanged, compared to its average volume of 207,060. Ascendis Pharma A/S has a one year low of $53.21 and a one year high of $133.96. The company has a market capitalization of $4.81 billion, a price-to-earnings ratio of -30.97 and a beta of 0.62. The company has a current ratio of 22.32, a quick ratio of 22.32 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average of $114.64 and a 200 day moving average of $110.74.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 30th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.44). The company had revenue of $6.15 million for the quarter, compared to analyst estimates of $0.66 million. Ascendis Pharma A/S had a negative return on equity of 34.64% and a negative net margin of 901.89%. Analysts predict that Ascendis Pharma A/S will post -5.46 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. Chartwell Investment Partners LLC boosted its holdings in Ascendis Pharma A/S by 1.4% during the 2nd quarter. Chartwell Investment Partners LLC now owns 20,917 shares of the biotechnology company’s stock valued at $2,409,000 after acquiring an additional 280 shares during the period. International Biotechnology Trust PLC boosted its holdings in Ascendis Pharma A/S by 87.0% during the 2nd quarter. International Biotechnology Trust PLC now owns 25,800 shares of the biotechnology company’s stock valued at $2,969,000 after acquiring an additional 12,000 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Ascendis Pharma A/S by 53.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,178,036 shares of the biotechnology company’s stock valued at $826,551,000 after acquiring an additional 2,509,034 shares during the period. OneAscent Financial Services LLC purchased a new stake in Ascendis Pharma A/S during the 2nd quarter valued at about $448,000. Finally, Victory Capital Management Inc. boosted its holdings in Ascendis Pharma A/S by 5.6% during the 2nd quarter. Victory Capital Management Inc. now owns 340,908 shares of the biotechnology company’s stock valued at $39,256,000 after acquiring an additional 18,190 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: What Factors Can Affect Return on Equity?

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.